Innovation Pharmaceuticals Inc (IPIX)

[Justfactsmam]

rejoice...dont complain

raising capital (vs debt financing) = path to trials and success


ps NICE FIND ...GEORGE

Brilacidin Demonstrates Inhibition of SARS-CoV-2 in Cell Culture

https://www.mdpi.com/1999-4915/13/2/271 link shows number of times Peer Review Article was accessed as of Feb 9th and recited in other publications.

The abstract has been viewed over 2500 times and full artilce 500 times...Brilacidin getting known better in the scientific community.

________________________________________________________________________

Open AccessArticle
Brilacidin Demonstrates Inhibition of SARS-CoV-2 in Cell Culture
by Allison Bakovic 1,Kenneth Risner 1OrcID,Nishank Bhalla 1,Farhang Alem 1OrcID,Theresa L. Chang 2,Warren K. Weston 3,Jane A. Harness 3 andAarthi Narayanan 1,*
1
National Center for Biodefense and Infectious Diseases, George Mason University, Manassas, VA 20110, USA
2
Public Health Research Institute, Rutgers, New Jersey Medical School, the State University of New Jersey, Newark, NJ 07103, USA
3
Innovation Pharmaceuticals Inc., Wakefield, MA 01880, USA
*
Author to whom correspondence should be addressed.
Academic Editor: Deborah H. Fuller
Viruses 2021, 13(2), 271; https://doi.org/10.3390/v13020271
Received: 12 January 2021 / Revised: 28 January 2021 / Accepted: 5 February 2021 / Published: 9 February 2021
(This article belongs to the Section SARS-CoV-2 and COVID-19)
Download PDF Browse Figure Citation Export
Abstract
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), the newly emergent causative agent of coronavirus disease-19 (COVID-19), has resulted in more than two million deaths worldwide since it was first detected in 2019. There is a critical global need for therapeutic intervention strategies that can be deployed to safely treat COVID-19 disease and reduce associated morbidity and mortality. Increasing evidence shows that both natural and synthetic antimicrobial peptides (AMPs), also referred to as Host Defense Proteins/Peptides (HDPs), can inhibit SARS-CoV-2, paving the way for the potential clinical use of these molecules as therapeutic options. In this manuscript, we describe the potent antiviral activity exerted by brilacidin—a de novo designed synthetic small molecule that captures the biological properties of HDPs—on SARS-CoV-2 in a human lung cell line (Calu-3) and a monkey cell line (Vero). These data suggest that SARS-CoV-2 inhibition in these cell culture models is likely to be a result of the impact of brilacidin on viral entry and its disruption of viral integrity. Brilacidin demonstrated synergistic antiviral activity when combined with remdesivir. Collectively, our data demonstrate that brilacidin exerts potent inhibition of SARS-CoV-2 against different strains of the virus in cell culture.
Keywords: brilacidin; coronavirus; antiviral; defensin; peptidomimetic; entry inhibition